EG 005

Drug Profile

EG 005

Alternative Names: EG005

Latest Information Update: 09 Mar 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Class Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lipodystrophy

Most Recent Events

  • 07 Mar 2007 Discontinued - Phase-II for Lipodystrophy in United Kingdom (PO)
  • 05 Sep 2006 Initial results from a extension study of a phase II trial in lipodystrophy have been added to the Cancer therapeutic trials section
  • 30 Aug 2006 Ark Therapeutics has completed a 1-year voluntary extension study of a phase II trial in lipodystrophy in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top